Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of the ILB-3101 in Patients with Advanced Solid Tumors

NCT06426680 is registered in ClinicalTrials.gov with Innolake Biopharm as lead sponsor.

NCT NCT06426680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06426680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of the ILB-3101 in Patients with Advanced Solid Tumors
Lead sponsor
Innolake Biopharm
Phase
Phase 1
Overall status
Recruiting
Start date
October 30, 2024
Completion date
March 31, 2026
Enrollment
240 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor